Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Vermillion  (Stock symbol: VRML )

47350 Fremont Blvd.
Fremont, CA 94538
USA
(510) 226-2811
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) John F. Hamilton (Assertio Therapeutics Former CFO) Peter S. Roddy (Pain Therapeutics CFO) James S. Burns (EntreMed President/CEO) Cal Severinghaus (Tecan Americas President)
Former outside board: Judy Bruner (SanDisk CFO) Kenneth J. Conway (Starfire Ventures President) Rajan K. Dalal (Aviir CEO) William C. Wallen (IDEXX Laboratories Chief Scientific Officer) Michael J. Callaghan (MDS Capital Sr. VP) Barbara Dalton (SR One Limited);  Jean-Francois Formela (Accomplice{1});  William Green (Stanford Research Systems);  James Rathmann (Falcon Technology Partners) Daniel Vapnek (American General VP R&D);  Wendell Wierenga (Syrrx CEO) John A. Young (HP Former President/CEO)
Company

Business description: Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use.
Customers include: Abbott LaboratoriesAbgenixAmgenAstraZenecaBayerBristol-Myers SquibbCephalonEli LillyGlaxoSmithKlineHuman Genome SciencesNovartisPfizerProcterAndGambleQuest DiagnosticsRocheStanford UniversityStanford UniversityUniversity of Southern California;  Aventis;  BASF;  Beijing Normal University;  Biogen;  Boehringer Ingelheim;  Centocor;  Duke Medical School;  Harvard School of Public Health;  Johns Hopkins Medical School;  Lawrence Livermore National Laboratories;  Massachusetts General Hospital;  Massachusetts Institute of Technology;  McGill University;  MD Anderson Cancer Center;  MIT;  Monsanto;  Mount Sinai Medical School;  National Cancer Institute;  National Institutes of Health;  Ohio State University Commercialize ;  Osaka University;  Pharmacia;  Schering-Plough;  SmithAndNephew;  SmithKline;  Sumitomo Pharmaceuticals;  Takeda Chemical;  Tufts University;  Tulane University Medical Center;  UCLA;  University of Notre Dame;  Yamanouchi Pharmaceuticals
Partners include: Bio-Rad Laboratories NovartisPfizerQuest Diagnostics ;  Aaron Diamond AIDS Research Center;  ADDNET Consortium;  American Red Cross;  Beckman Coulter;  Ohio State University Research Foundation ;  SC Biosciences;  The Johns Hopkins University School of Medicine;  Universities Confederated Institute for Proteomics;  University of Texas M.D. Anderson Cancer Center;  Virginia Medical School;  Virginia Prostate Center
Capital

Rounds: 5
Capital raised: 25.5M
Ownership: Public  
Stock Symbol: VRML
VCs include: SR One Limited;  MDS Discovery Ventures Management;  Falcon Technology
Corporate investors: SmithKline

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2018
Sector: Medical
Year Founded: 1993
Headcount: 51-75 as of Feb 2019
Rounds: 5
Capital Raised: 25.5M
Ownership: Public  
Stock Symbol: VRML